December 2011 Issue of MMM
December 2011 issue
We are planning to host at least three more virtual events in 2012
Stephen Smith has helped build some remarkable businesses in the digital-medical space—starting with MedScape—with the wits of a tinkerer, not the smarm of a salesman.
To stave off federal budget cuts, the drug industry needs to show politicians its worth as a vital source of jobs, treatments and innovation
Sanford Bernstein's Tim Anderson, MD, who has taken Institutional Investor's top ranking three years running, on what 2012 has in store
Profiling a dozen agents on deck plus many products in the wings, MM&M's Pipeline 2012 sees a year of change.
Choosing channels and creating an integrated campaign isn't easy, but our panel of experts can help. James Chase directs the discussion
Wrapping up what was remarkable about the past year, and pondering how the New Year will be the same and/or different.
Does Crestor have a selective advantage over Lipitor that would make it worth the price difference?
A little over half of US girls ages 13 to 17 have not gotten even one dose of the HPV vaccine
Amylin will raise its number of sales reps from 350 to 715 to make up for Eli Lilly's departure from commercial activities
Sanofi will winnow its field force down through a "voluntary separation program" and relocation of some reps, said a spokesperson following news of more layoffs
News on Biogen Idec, inVentiv Health, Abbott and Gilead Sciences
Wolters Kluwer has reached an agreement to sell its pharma-related marketing and publishing services unit to Springer Science+Business Media.
The Association of Medical Media (AMM) named its Doctors' Choice award winners, and Interpublic Group and Omnicom agencies dominated.
News on BMJ, Docphin, Quadrant HealthCom and BMJ.com
Pharma DTC ad spend rose 4% through July 2011, vs. YTD July 2010, according to SDI, with magazine buys up 18%. Why is print up?
David Kramer, who co-founded the agency now known as Digitas Health in 1988, announced that he will leave the company at year's end.
Consumers are concerned about online privacy, but marketers tracking their surfing habits or mining their emails is the least of their worries
Digital Media briefs: Everyday Health, HealthPrize Technologies, Boston Scientific, BBK Worldwide and PatientsLikeMe
News on Everyday Health, HealthPrize Technologies, Boston Scientific, BBK Worldwide and PatientsLikeMe
New online and print DTC advertising for Benlysta, targeting US patients with lupus, are launching this month, said executives from Human Genome Sciences.
Even I know about the portable MRI machine by Sonosite, thanks to its comic-book-style DTC campaign
Everyday Health is launching a YouTube channel, "Everyday Health TV: Content to Change Your Life."
Out of 240 branded pharma websites, only about a fifth have any African American imagery on their pages, and bilingual sections of pharma sites are ...
IMS Health's acquisition of SDI Health was officially consummated, and its parent company is moving forward to divest two SDI product lines
Social media has emerged as a deep well of opinion but is an enigma for market researchers, says the co-founder of EmPower Research.
Merck consolidated the advertising and promotion business on its respiratory franchise to Interpublic, with Draftfcb Healthcare's Area 23 serving as lead agency.
Agency CAHG became the first healthcare marketing shop to get training and certification in regulatory compliance from the Center for Communication Compliance.
Agency Business briefs: Euro RSCG Life LM&P, Publicis Touchpoint Solutions, Cooney/Waters Group and Vox Collective
News on Euro RSCG Life LM&P, Publicis Touchpoint Solutions, Cooney/Waters Group and Vox Collective
Risk management means more than REMS strategies and tactics, or validated methodologies and therapeutic registries. What it's really about is assuming the mantle of responsibility.
Sens. Richard Blumenthal and Bob Corker introduce the Generating Antibiotic Initiatives Now (GAIN) Act to spur antibiotic development to fight the spread of antibiotic-resistant bacteria.
FDA drugs director Janet Woodcock says the next 25 years could bring advances with the potential to make drug development more reliable—and decrease regulatory oversight
The logistical costs of face-to-face advisory board meetings don't help manufacturers or thought leaders
It is counterintuitive to place a burden on information that adds value to public health and safety
Some current campaigns in oncology—with one example from the consumer world—that raise awareness and educate in a provocative and compelling manner
At Work With
Scott Weintraub: Chief Marketing Officer, Principal, HRM—Healthcare Regional Marketing
Name That Brand
A tidal wave of information is on the horizon. Processing, analyzing and drawing accurate conclusions from that information is healthcare's next major challenge.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.